MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that Lisa Earnhardt will be stepping down from her role as Chief Executive Officer on June 5, 2019 to accept another opportunity.
Kieran Gallahue, the company’s Lead Director, has been appointed Executive Chairman of the Board of Directors, effective May 7, 2019, and Interim Chief Executive Officer, effective June 5, 2019. Ms. Earnhardt will remain a member of the Intersect ENT Board.
“It has been an honor to lead Intersect ENT the past 11 years,” said Ms. Earnhardt. “I am extremely proud of all that we have accomplished. Together we have worked with physicians to improve the lives of over 300,000 patients, and the team is laser focused on making localized drug delivery the standard of care for chronic sinusitis sufferers. I look forward to watching this exceptional team continue to deliver over the coming years.”
Mr. Gallahue said, “On behalf of the Board and entire team, I want to thank Lisa for her many contributions to our company, and wish her the best. Under her leadership, Intersect ENT has become the leader in evidence-based innovation in the ENT specialty, and I’m excited to take an expanded role during this important time for the company. I look forward to working closely with the talented Intersect ENT team as we continue to drive growth across our portfolio and deliver value for our shareholders.”
The Intersect ENT Board has initiated a search process to identify a permanent CEO and has engaged a leading executive search firm to assist with this process.
In a separate press release to be issued today, Intersect ENT will report financial results for the first quarter of fiscal year 2019. The previously scheduled conference call will be held today at 4:30 pm ET. To access the conference call via the internet, go to the "Investor Relations" page of the Company's website at www.intersectENT.com. To access the live conference call via phone, dial (844) 850-0548 and ask to join the Intersect ENT call. International callers may access the live call by dialing (412) 317-5205. Participants may expedite telephone access by pre-registering for the call using the following link: http://dpregister.com/10130111.
A replay of the conference call may be accessed one to two hours after the call at www.intersectent.com or via phone at (877) 344-7529 or (412) 317-0088 for international callers. The reference number to enter the replay of the call is 10130111. The dial-in replay will be available for a week after the call, and via the internet for approximately one month.
About Kieran Gallahue
Kieran Gallahue has served as Intersect ENT’s Lead Director and member of the Board’s Audit Committee since April 2015. He has more than 20 years of strategic, operational and corporate management experience in the healthcare industry, with deep expertise in the medical technologies field. He previously served as Chairman and CEO at CareFusion from 2011 until March 2015, and prior to that, he was President, CEO and a Director of ResMed. Mr. Gallahue also currently serves on the Board of Directors at Edwards Lifesciences, a global leader in the science of heart valves and hemodynamic monitoring, and Arena Pharmaceuticals, a biopharmaceutical company focused on delivering novel, transformational medicines across multiple therapeutic areas. He holds a bachelor’s degree in economics from Rutgers University and a master’s degree from Harvard Business School.
About Intersect ENT®
Intersect ENT is dedicated to transforming ear, nose and throat care by providing innovative, clinically meaningful therapies to physicians and patients. The company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.
For additional information on the company or the products including risks and benefits please visit www.IntersectENT.com.